News

A specific population of nerve cells in the brain that helps to regulate REM sleep may be a key target for treating Parkinson’s disease, a study demonstrates. REM (rapid eye movement) is the stage of sleep where the most dreaming occurs, with its other three stages classified as either…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced an initiative to accelerate the identification of biomarkers and the development of new therapies targeting the LRRK2 gene, one of the most common causes of inherited Parkinson’s disease. The program, LRRK2 Investigative Therapeutics Exchange, or LITE, provides “tens…

The American Parkinson Disease Association (APDA) is funding a new APDA Center for Advanced Research at Yale University’s School of Medicine, the newest of nine such centers in its U.S. network, in recognition of the school’s work into the causes and the potential for personalized treatment of Parkinson’s…

The U.S. Food and Drug Administration (FDA) has approved foslevodopa and foscarbidopa, a levodopa therapy given as a 24-hour under-the-skin infusion, to treat motor fluctuations in adults with advanced Parkinson’s disease. The newly approved therapy, which had been known as ABBV-951 while in development, will be sold by…

Fatigue is the most common complaint among people with Parkinson’s disease, according to anecdotal data from a free app that allows patients or caregivers to complete daily check-ins and rate how they feel. In the nine months since the launch of Parkinson’s On, more than 2,500 patients and caregivers…

Allyx Therapeutics has received a $3.3 million grant from the National Institutes of Health (NIH) to initiate a Phase 1 clinical trial to evaluate the interaction of its investigational oral therapy ALX-001 with other medications and assess how the drug can affect patients who take multiple medications. The grant,…

Researchers have identified six probiotics — live bacteria usually used as dietary supplements to help with digestion — with the potential to be used as an add-on to standard treatment for Parkinson’s disease. In a study with bacteria collected from fecal samples, the researchers observed that the bacterial strains…

Treatment with the experimental gene therapy AAV-GAD led to significant easing of motor symptoms and improved life quality for most people with Parkinson’s disease in an early clinical trial, according to new data announced by the therapy’s developer MeiraGTx. “We are excited about these impressive clinical data…

A novel technology based on gene therapy enables precise and noninvasive control of specific brain circuits using magnetic fields, allowing select nerve cells to be turned on or off, a study reports. This magnetogenetics technology — a result of collaboration between Weill Cornell Medicine at Cornell University, The Rockefeller University,…

Neural microtissues derived from pluripotent stem cells (iPSCs) can replace dopaminergic neurons, the nerve cells that are lost in Parkinson’s disease, and restore motor function when grown into tiny capsules and transplanted into the brains of model rats, a study led by TreeFrog Therapeutics found. “TreeFrog Therapeutics has…